Mana.bio specializes in AI-based drug-delivery solutions, with a focus on gene therapy. The companys technology integrates machine learning and nanotechnology for the development of drug-delivery systems. Mana.bio has created a platform for lipid nanoparticle development for oligonucleotide therapies, including mRNA-based therapeutics, vaccines, and gene therapy. The technology is powered by an integration of machine learning and nanotechnology in order to identify formulations of lipid nanoparticles drug delivery systems.